2017 Public Policy Comments

  • October 30 – OCAN statement — applauding the USP for establishing a new class for anti-obesity agents and including all FDA-approved drugs under the list of “Example Drugs” – both in the single entity list and combination list of the latest version of the proposed USP-DC. To view the full comment, CLICK HERE.